WO2006091962A3 - Detection of compounds that affect therapeutic activity - Google Patents

Detection of compounds that affect therapeutic activity Download PDF

Info

Publication number
WO2006091962A3
WO2006091962A3 PCT/US2006/006986 US2006006986W WO2006091962A3 WO 2006091962 A3 WO2006091962 A3 WO 2006091962A3 US 2006006986 W US2006006986 W US 2006006986W WO 2006091962 A3 WO2006091962 A3 WO 2006091962A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
detection
therapeutic activity
affect therapeutic
affect
Prior art date
Application number
PCT/US2006/006986
Other languages
French (fr)
Other versions
WO2006091962A2 (en
Inventor
Shuqian Jing
Francesca Civoli
Shalini Gupta
Daniel Steven Halperin
Jason Joseph Pennucci
Steven Swanson
Yan Bin Yu
Original Assignee
Amgen Inc
Shuqian Jing
Francesca Civoli
Shalini Gupta
Daniel Steven Halperin
Jason Joseph Pennucci
Steven Swanson
Yan Bin Yu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Shuqian Jing, Francesca Civoli, Shalini Gupta, Daniel Steven Halperin, Jason Joseph Pennucci, Steven Swanson, Yan Bin Yu filed Critical Amgen Inc
Priority to EP06736328A priority Critical patent/EP1853913A2/en
Publication of WO2006091962A2 publication Critical patent/WO2006091962A2/en
Publication of WO2006091962A3 publication Critical patent/WO2006091962A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Abstract

The present invention relates to methods of detecting compounds that affect the activity of a therapeutic substance or composition administered to a subject, and to reagents for use in such methods.
PCT/US2006/006986 2005-02-24 2006-02-23 Detection of compounds that affect therapeutic activity WO2006091962A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06736328A EP1853913A2 (en) 2005-02-24 2006-02-23 Detection of compounds that affect therapeutic activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65669605P 2005-02-24 2005-02-24
US60/656,696 2005-02-24

Publications (2)

Publication Number Publication Date
WO2006091962A2 WO2006091962A2 (en) 2006-08-31
WO2006091962A3 true WO2006091962A3 (en) 2007-03-29

Family

ID=36928128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/006986 WO2006091962A2 (en) 2005-02-24 2006-02-23 Detection of compounds that affect therapeutic activity

Country Status (3)

Country Link
US (1) US20060211022A1 (en)
EP (1) EP1853913A2 (en)
WO (1) WO2006091962A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ601659A (en) * 2008-09-26 2014-02-28 Ambrx Inc Modified animal erythropoietin polypeptides and their uses
GB0905973D0 (en) * 2009-04-07 2009-05-20 Univ Edinburgh Detection and/or treatment of diseases associated with autoantibodies
EP2968469A4 (en) 2013-03-15 2016-08-31 Longevity Biotech Inc Peptides comprising non-natural amino acids and methods of making and using the same
JP6757942B2 (en) * 2016-08-03 2020-09-23 東洋鋼鈑株式会社 Buffer composition for hybridization and hybridization method

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008822A1 (en) * 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
WO1994029458A1 (en) * 1993-06-07 1994-12-22 Amgen Inc. Hybrid receptor molecules
EP1167386A1 (en) * 2000-06-26 2002-01-02 Pfizer Products Inc. Canine and feline melanocortin-4 receptor sequences and screening assays to identify compounds useful in regulating animal appetite and metabolic rate
US20040082773A1 (en) * 2002-06-28 2004-04-29 Pfizer Inc. Modified PAR receptors, their preparation and their uses for selecting compounds which modulate PAR activity
US20040137517A1 (en) * 2000-12-22 2004-07-15 Andrews John Leon Method of screening for gpr40 ligands

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008822A1 (en) * 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
WO1994029458A1 (en) * 1993-06-07 1994-12-22 Amgen Inc. Hybrid receptor molecules
EP1167386A1 (en) * 2000-06-26 2002-01-02 Pfizer Products Inc. Canine and feline melanocortin-4 receptor sequences and screening assays to identify compounds useful in regulating animal appetite and metabolic rate
US20040137517A1 (en) * 2000-12-22 2004-07-15 Andrews John Leon Method of screening for gpr40 ligands
US20040082773A1 (en) * 2002-06-28 2004-04-29 Pfizer Inc. Modified PAR receptors, their preparation and their uses for selecting compounds which modulate PAR activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHYAMALA VENKATAKRISHNA ET AL: "High-throughout screening for ligand-induced c-fos mRNA expression by branched DNA assay in Chinese hamster ovary cells", ANALYTICAL BIOCHEMISTRY, vol. 266, no. 1, 1 January 1999 (1999-01-01), pages 140 - 147, XP002398530, ISSN: 0003-2697 *

Also Published As

Publication number Publication date
US20060211022A1 (en) 2006-09-21
WO2006091962A2 (en) 2006-08-31
EP1853913A2 (en) 2007-11-14

Similar Documents

Publication Publication Date Title
EP2020445A4 (en) Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease
TWI320316B (en) Methods for inhibiting hscd activity,pyridazine derivatives and use and pharmaceutical composition thereof
CL2007002017A1 (en) COMPOUNDS DERIVED FROM [4,5 '] - BIPIRIMIDINIL-6,4'-DIAMINE; PHARMACEUTICAL COMPOSITION; AND USE AS AN INHIBITOR OF THE ACTIVITY OF CINASA IN CANCER DE VEJIGA, CANCER CERVICAL AND MIELOMA MULTIPLE.
NO2012017I1 (en) Benzimidazole derivative, process for its preparation, drug containing this compound and use of the compound.
WO2007056681A3 (en) Methods for administering hypoglycemic agents
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
EP1954190A4 (en) Blood analyte determinations
IL188050A (en) Azaindazole derivatives, pharmaceutical compositions containing the same and uses thereof
EP1638950A4 (en) Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1984370A4 (en) Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
IL190951A0 (en) Method of acting upon organism by targeted delivery of biologicaly active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
HK1103393A1 (en) Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
MY153198A (en) Inhibitors of protein aggregation
IL195528A (en) Pyridazine compound, methods for its preparation, pharmaceutical composition comprising the same, use thereof and intermediate
WO2009137062A3 (en) Photoactivatable antimicrobial agents and therapeutic and diagnostic methods of using same
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
EP2097507A4 (en) Analyte sensors, methods for preparing and using such sensors, and methods of detecting analyte activity
IL187713A0 (en) 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof
CL2007002887A1 (en) COMPOUNDS DERIVED FROM HETEROCICLES, METALOPROTEINASE IN MATRIX INHIBITORS (MMP); INTERMEDIARY COMPOUND; PHARMACEUTICAL COMPOSITION; PHARMACEUTICAL KIT; AND USE IN THE PREVENTION AND TREATMENT IN CONDITIONS AFFECTED BY METALOPROTEINASES OF THE MAT
WO2006128041A3 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
ZA200711105B (en) Novel physiological substance nesfatin substance relevant thereto, and use of the substances
EP1873522A4 (en) Method for determination of hemoglobin derivative, and reagent composition, assay kit, analysis device and analysis system for use in the method
WO2007120156A3 (en) Animal models of long qt syndrome and uses thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006736328

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application